Doxorubicin is a powerful medicine used to treat certain types of cancer. It works by stopping the growth of cancer cells. It's often given in cycles, meaning it's taken for a period, then stopped, and then started again. It's usually given through an IV line into a vein.
Every report comes from a Lived member, sent anonymously.
Have you tried Adriamycin (Doxorubicin) for Breast Cancer?
Doxorubicin, sold under the brand name Adriamycin and as a generic, is a chemotherapy drug used against a wide range of cancers. It is one of the standard medicines for early breast cancer that has spread to the lymph nodes in the armpit, where it is given after surgery alongside other chemotherapy to lower the chance of the cancer returning. It is also used for acute lymphoblastic and acute myeloid leukemia, Hodgkin and non-Hodgkin lymphoma, soft tissue and bone sarcomas, and some advanced cancers of the breast, ovary, bladder, stomach, thyroid and lung. In children, it is part of treatment for Wilms tumor (a kidney cancer) and neuroblastoma (a cancer of developing nerve cells). Doxorubicin belongs to a family of drugs called anthracyclines. It is usually one part of a combination regimen rather than given alone; the familiar "AC" breast cancer regimen, for example, pairs it with cyclophosphamide. Liposomal doxorubicin, known by the brand name Doxil, contains the same active drug packaged inside tiny fat-based particles. It is a different product with its own uses (certain ovarian cancers, AIDS-related Kaposi sarcoma and multiple myeloma), dosing and side effects, and the two are not substituted for each other.
Cancer cells divide rapidly, and each division requires copying the cell's DNA. Doxorubicin slips between the strands of DNA and blocks an enzyme called topoisomerase II, which cells need to untangle and rejoin DNA while copying it. The result is DNA breaks that the cell cannot repair, so it stops dividing and dies. This effect is strongest in fast-dividing cells, which is why it works against cancer but also affects healthy tissues that renew quickly, such as bone marrow, hair follicles and the lining of the mouth and gut. Doxorubicin can also injure heart muscle cells through a separate process, which is why the total amount a person receives over a lifetime is carefully tracked.
Doxorubicin is given only by a trained oncology team, as an injection into a vein over several minutes or, for some regimens, as a longer infusion through a central line (a thin tube placed in a large vein in the chest). Treatment comes in cycles, typically one dose every three or four weeks, with time in between for the body to recover. In early breast cancer, a common plan is four cycles given three weeks apart together with cyclophosphamide. The dose is calculated from body surface area, written as milligrams per square meter (mg/m²), and is adjusted for liver function, blood counts, earlier cancer treatment and age. Each dose adds to a running lifetime total that the team keeps track of, including other anthracyclines received in the past. Doxorubicin can badly damage skin and tissue if it leaks out of the vein during the infusion. Tell the nurse immediately about any burning, stinging, pain or swelling at the IV site, even if it seems minor. Many people receive it through a port or central line partly to reduce this risk.
Hair loss is very common and usually begins a few weeks after the first dose; it typically grows back after treatment ends. Nausea and vomiting are also common, and anti-nausea medicines are normally given before each dose. Mouth sores, diarrhea, tiredness and darkening of the skin or nails can occur. Red or orange urine for a day or two after each dose is expected and comes from the drug's color, not from bleeding. Doxorubicin lowers blood counts, with white blood cells usually reaching their lowest point about 10 to 14 days after a dose and recovering by around three weeks. During that window, infections can become serious quickly. A fever of 100.4°F (38°C) or higher, or chills with shaking, needs a call to the oncology team right away, at any hour. Also call if vomiting, diarrhea or mouth sores keep you from eating or drinking. The most important long-term risk is damage to the heart muscle, which can weaken its pumping and lead to heart failure. The risk climbs with the lifetime total dose: roughly 1 to 2 in 100 people at a total of 300 mg/m², rising to between 6 and 20 in 100 at 500 mg/m². It can appear during treatment or years later. Shortness of breath, swelling of the feet or ankles, a fast or irregular heartbeat or unusual exhaustion, during or after treatment, should be reported to the care team promptly.
Some cancer treatments add to doxorubicin's strain on the heart, including radiation to the chest and trastuzumab (Herceptin), an antibody treatment for HER2-positive breast cancer. Doxorubicin and trastuzumab are not given at the same time, and the timing of one after the other is planned carefully. Other medicines can raise or lower doxorubicin levels in the body, including verapamil (a heart and blood pressure medicine), the seizure medicines phenytoin and phenobarbital, and the herbal supplement St. John's wort. Share a complete list of medicines and supplements with the oncology team. Doxorubicin can seriously harm a developing baby. Women who could become pregnant should use highly effective contraception during treatment and for 6 months afterward, and men with partners who could become pregnant should use contraception for the same period. Breastfeeding is not advised during treatment. Doxorubicin can cause infertility in both men and women and can bring on early menopause, so questions about fertility preservation are best raised before treatment starts. Doxorubicin also slightly raises the risk of a second blood cancer, acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS, a bone marrow disorder), usually within 1 to 3 years after treatment. In studies of breast cancer treatment, this affected about 1.5 in 100 people over 10 years. People who have had radiation can develop a flare of skin redness or lung inflammation in the treated area, called radiation recall. Doxorubicin is generally not given to people with severe heart failure, a heart attack within the past four to six weeks, very low blood counts from earlier treatment or severe liver disease.
Before the first dose, the team checks heart pumping strength with an echocardiogram (an ultrasound of the heart) or a MUGA scan (a nuclear scan of the heart), along with blood counts and liver tests. Blood counts are checked before each cycle, and a dose may be delayed if they have not recovered. Heart scans are repeated during treatment, more often as the lifetime total grows. In some people approaching higher totals, a heart-protecting medicine called dexrazoxane may be added. The days right after each dose are often the hardest for nausea and fatigue, and the second week tends to carry the highest infection risk. Many people settle into a predictable pattern across cycles. Hair and most other side effects recover after treatment ends, while effects on fertility and the heart can be lasting. Because heart damage can show up years later, people who have received doxorubicin, especially children and those who also had chest radiation, are advised to have periodic heart checks for the long term and to mention their past treatment to any future doctors.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Adriamycin (Doxorubicin), what you've noticed, or ask the community a question.